CYCLERION THERAPEUTICS CYCN 深 沪
已收盘 08-21 16:00:00 美东时间
3.89
-0.180
-4.42%
华盛通- 最 高4.2883
- 今 开4.07
- 成交量 6.57万股
- 最 低 3.78
- 昨 收 4.07
- 总市值 1821.05万
- 52周最高 8.48
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 1.0266
- 委 比 22.69%
- 总股本 468.14万
- 历史最高 296.60
- 量 比 2.13
- 振 幅 12.49%
- 历史最低 1.0266
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cyclerion Therapeutics Q1 EPS $(0.76) Down From $(0.56) YoY
Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.76) per share. This is a 35.71 percent decrease over losses of $(0.56) per share from the same period last year.
05-13 05:32
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-10 03:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
Cyclerion Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement with Korsana Biosciences.
Cyclerion Therapeutics shares are trading higher after the company announced it...
04-01 19:28
Eli Lilly and Co Stock (LLY) Moved Up by 5.46% on Apr 1: Facts Behind the Movement
• Eli Lilly to acquire Centessa Pharmaceuticals for up to $7.8 billion. • Acquisition expands neuroscience portfolio into sleep-wake disorders. • Analysts maintain "Buy" ratings with substantial upside price targets.
04-01 14:15
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Cyclerion Therapeutics has received positive regulatory feedback from the FDA for its Phase 2 POC study of CYC-126 for treatment-resistant depression (TRD). CYC-126, an anesthetic-based therapy using real-time EEG feedback, aims to address TRD through individualized, precision delivery. The FDA supports the study design, leveraging approved anesthetics, allowing Cyclerion to remain on track to initiate the trial in late 2026. Additionally, the co...
02-17 12:00
